| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| ADMA BioManufacturing | | | | 22.2 | 6.8 | 11.0 | | |
| Plasma Collection Centers | | | | 7.0 | 10.0 | 11.6 | 10.5 | 7.1 |
| Corporate | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Other | 153.9 | 80.8 | 42.1 | | | | | |
| Total revenues [+] | 154.1 | 80.9 | 42.2 | 29.3 | 17.0 | 22.8 | 10.7 | 7.2 |
| Licensing | | | | 0.1 | 0.1 | 0.1 | 0.1 | |
| Products | | | | 29.2 | 16.8 | 15.6 | 10.5 | 7.1 |
| Other income | | | | | | 7.0 | | |
| Revenue growth [+] | 90.4% | 91.7% | 43.9% | 72.8% | -25.4% | 113.5% | 48.5% | 21.3% |
| ADMA BioManufacturing | | | | 226.2% | -38.1% | | | |
| Plasma Collection Centers | | | | -30.0% | -13.7% | 10.6% | 49.2% | 20.7% |
| Corporate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 12.2% | 68.6% |
| Cost of goods sold | 118.8 | 79.8 | 61.3 | 39.5 | 42.2 | 29.2 | 6.4 | 4.3 |
| Gross profit | 35.3 | 1.2 | -19.1 | -10.2 | -25.2 | -6.4 | 4.3 | 2.9 |
| Gross margin | 22.9% | 1.4% | -45.2% | -34.6% | -148.4% | -28.1% | 40.3% | 39.9% |
| Selling, general and administrative [+] | 52.5 | 42.9 | 35.1 | 25.9 | 22.5 | 18.8 | 8.5 | 6.7 |
| General and administrative [+] | | | | 25.9 | 22.5 | 18.8 | 8.5 | 6.7 |
| General and administrative expenses | | | | 25.9 | 22.5 | 18.8 | 8.5 | 6.7 |
| Research and development | 3.6 | 3.6 | 5.9 | 2.3 | 3.9 | 5.6 | 7.7 | 7.0 |
| Other operating expenses | 17.8 | 12.3 | 4.2 | 2.2 | 7.8 | 7.7 | 5.4 | |
| EBITDA [+] | -32.3 | -52.9 | -61.0 | -38.2 | -56.8 | -35.8 | -16.9 | -15.0 |
| EBITDA growth | -39.0% | -13.3% | 59.8% | -32.9% | 58.9% | 112.2% | 12.1% | -4.6% |
| EBITDA margin | -20.9% | -65.3% | -144.4% | -130.0% | -334.7% | -157.2% | -158.2% | -209.6% |
| Depreciation and amortization | 6.4 | 4.8 | 3.2 | 2.4 | 2.6 | 1.5 | 0.5 | 0.5 |
| EBITA | -38.6 | -57.7 | -64.2 | -40.6 | -59.4 | -37.2 | -17.3 | -15.5 |
| EBITA margin | -25.1% | -71.2% | -152.1% | -138.3% | -350.0% | -163.6% | -162.6% | -216.1% |
| Amortization of intangibles | 0.7 | 0.7 | 0.7 | 0.8 | 0.8 | 1.2 | | |
| EBIT [+] | -39.4 | -58.4 | -64.9 | -41.4 | -60.3 | -38.5 | -17.3 | -15.5 |
| EBIT growth | -32.6% | -10.1% | 56.7% | -31.3% | 56.7% | 121.9% | 11.7% | -3.2% |
| EBIT margin | -25.5% | -72.1% | -153.8% | -141.1% | -354.9% | -169.0% | -162.6% | -216.1% |
| Non-recurring items [+] | | | | | | 0.8 | | |
| Asset impairment | | | | | | 0.8 | | |
| Interest expense, net [+] | 19.2 | 13.0 | 11.7 | 8.2 | 5.3 | 3.2 | 2.2 | 1.8 |
| Interest expense | 19.3 | 13.1 | 12.0 | 9.0 | 5.5 | 3.3 | 2.2 | 1.8 |
| Interest income | 0.0 | 0.0 | 0.3 | 0.8 | 0.2 | 0.1 | 0.1 | 0.0 |
| Other income (expense), net [+] | -7.3 | -0.3 | 0.9 | 1.3 | -0.1 | -1.2 | 0.0 | -0.7 |
| Gain (loss) on debt retirement | -6.7 | | 1.0 | -10.0 | | -1.2 | | -0.7 |
| Other | -0.6 | -0.3 | -0.1 | -0.2 | -0.1 | 0.0 | 0.0 | |
| Pre-tax income | -65.9 | -71.6 | -75.7 | -48.3 | -65.7 | -43.8 | -19.5 | -18.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -65.9 | -71.6 | -75.7 | -48.3 | -65.7 | -43.8 | -19.5 | -18.0 |
| Net margin | -42.8% | -88.5% | -179.4% | -164.5% | -387.1% | -192.3% | -183.1% | -250.4% |
| |
| Basic EPS [+] | ($0.33) | ($0.51) | ($0.88) | ($0.89) | ($1.45) | ($1.91) | ($1.61) | ($1.73) |
| Growth | -35.1% | -41.6% | -1.0% | -38.9% | -23.9% | 19.0% | -7.0% | -4.6% |
| Diluted EPS [+] | ($0.33) | ($0.51) | ($0.88) | ($0.89) | ($1.45) | ($1.91) | ($1.61) | ($1.73) |
| Growth | -35.1% | -41.6% | -1.0% | -38.9% | -23.9% | 19.0% | -7.0% | -4.6% |
| |
| Shares outstanding (basic) [+] | 197.9 | 139.6 | 86.1 | 54.3 | 45.2 | 22.9 | 12.2 | 10.4 |
| Growth | 41.8% | 62.0% | 58.5% | 20.3% | 97.4% | 88.4% | 16.7% | 12.1% |
| Shares outstanding (diluted) [+] | 197.9 | 139.6 | 86.1 | 54.3 | 45.2 | 22.9 | 12.2 | 10.4 |
| Growth | 41.8% | 62.0% | 58.5% | 20.3% | 97.4% | 88.4% | 16.7% | 12.1% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |